Loading
PDBj
MenuPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help
Search by PDB author
4R1Y
DownloadVisualize
BU of 4r1y by Molmil
Identification and optimization of pyridazinones as potent and selective c-Met kinase inhibitor
Descriptor: 2-(2-(2-(2-(2-(2-ETHOXYETHOXY)ETHOXY)ETHOXY)ETHOXY)ETHOXY)ETHANOL, 3-(diethylamino)propyl (3-{[5-(3,4-dimethoxyphenyl)-2-oxo-2H-1,3,4-thiadiazin-3(6H)-yl]methyl}phenyl)carbamate, Hepatocyte growth factor receptor
Authors:Blaukat, A, Bladt, F, Friese-Hamim, M, Knuehl, C, Fittschen, C, Graedler, U, Meyring, M, Dorsch, D, Stieber, F, Schadt, O.
Deposit date:2014-08-08
Release date:2015-03-18
Last modified:2024-02-28
Method:X-RAY DIFFRACTION (2 Å)
Cite:Identification and optimization of pyridazinones as potent and selective c-Met kinase inhibitors.
Bioorg.Med.Chem.Lett., 25, 2015
4R1V
DownloadVisualize
BU of 4r1v by Molmil
Identification and optimization of pyridazinones as potent and selective c-Met kinase inhibitors
Descriptor: 3-[1-(3-{5-[(1-methylpiperidin-4-yl)methoxy]pyrimidin-2-yl}benzyl)-6-oxo-1,6-dihydropyridazin-3-yl]benzonitrile, GAMMA-BUTYROLACTONE, Hepatocyte growth factor receptor
Authors:Blaukat, A, Bladt, F, Friese-Hamim, M, Knuehl, C, Fittschen, C, Graedler, U, Meyring, M, Dorsch, D, Stieber, F, Schadt, O.
Deposit date:2014-08-07
Release date:2015-03-18
Last modified:2024-02-28
Method:X-RAY DIFFRACTION (1.2 Å)
Cite:Identification and optimization of pyridazinones as potent and selective c-Met kinase inhibitors.
Bioorg.Med.Chem.Lett., 25, 2015
3LW0
DownloadVisualize
BU of 3lw0 by Molmil
IGF-1RK in complex with ligand MSC1609119A-1
Descriptor: 3-cyano-N-{1-[4-(5-cyano-1H-indol-3-yl)butyl]piperidin-4-yl}-1H-indole-7-carboxamide, GLYCEROL, Insulin-like growth factor 1 receptor
Authors:Graedler, U, Heinrich, T, Boettcher, H, Blaukat, A, Shutes, A, Askew, B.
Deposit date:2010-02-23
Release date:2010-09-29
Last modified:2023-11-01
Method:X-RAY DIFFRACTION (1.79 Å)
Cite:Allosteric IGF-1R Inhibitors.
Acs Med.Chem.Lett., 1, 2010
5BNJ
DownloadVisualize
BU of 5bnj by Molmil
CDK8/CYCC IN COMPLEX WITH 8-{3-Chloro-5-[4-(1-methyl-1H-pyrazol-4-yl)-phenyl]-pyridin- 4-yl}-2,8-diaza-spiro[4.5]decan-1-one
Descriptor: 8-{3-chloro-5-[4-(1-methyl-1H-pyrazol-4-yl)phenyl]pyridin-4-yl}-2,8-diazaspiro[4.5]decan-1-one, Cyclin-C, Cyclin-dependent kinase 8, ...
Authors:Musil, D, Blagg, J, Wienke, D.
Deposit date:2015-05-26
Release date:2015-10-14
Last modified:2024-05-08
Method:X-RAY DIFFRACTION (2.64 Å)
Cite:A selective chemical probe for exploring the role of CDK8 and CDK19 in human disease.
Nat.Chem.Biol., 11, 2015
3C09
DownloadVisualize
BU of 3c09 by Molmil
Crystal structure the Fab fragment of matuzumab (Fab72000) in complex with domain III of the extracellular region of EGFR
Descriptor: 2-acetamido-2-deoxy-beta-D-glucopyranose, Epidermal growth factor receptor, Matuzumab Fab Heavy chain, ...
Authors:Ferguson, K.M, Schmiedel, J, Knoechel, T.
Deposit date:2008-01-18
Release date:2008-04-15
Last modified:2023-11-01
Method:X-RAY DIFFRACTION (3.2 Å)
Cite:Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization.
Cancer Cell, 13, 2008
3C08
DownloadVisualize
BU of 3c08 by Molmil
Crystal structure the Fab fragment of matuzumab/EMD72000 (Fab72000)
Descriptor: Matuzumab Fab Heavy chain, Matuzumab Fab Light chain, SULFATE ION
Authors:Ferguson, K.M, Schmiedel, J, Knoechel, T.
Deposit date:2008-01-18
Release date:2008-04-15
Last modified:2023-11-01
Method:X-RAY DIFFRACTION (2.15 Å)
Cite:Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization.
Cancer Cell, 13, 2008

221371

PDB entries from 2024-06-19

PDB statisticsPDBj update infoContact PDBjnumon